Antibody response following SARS-CoV-2 infection and implications for immunity : final update of a rapid, living review / Haley K. Holmer [and 6 others]
In January 2022, we published an evolving rapid review, meta-analysis, and data visualization that compared the risk of reinfection in adults with prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to the risk of infection in adults without a prior infection. We found that prior infection with the Alpha variant or the wild-type SARS-CoV-2 virus reduced the risk of another infection by 80–97 percent (pooled estimate 87%; 95% confidence interval [CI] 84–90%) compared with uninfected individuals in studies with a median followup of 8 months (range 4 to 13 months). Protection remained above 80 percent for at least 7 months. Our original review, published in March 2021,2 described the antibody response after infection with the SARS-CoV-2 virus, but found little information on the duration of the response beyond 6 months or on antibody formation in asymptomatic patients or in individuals who are immunocompromised..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
July 2022 |
|---|---|
| Erschienen: |
Rockville, Md.: Agency for Healthcare Research and Quality ; July 2022 |
| Ausgabe: |
Version 3.0. |
| Reihe: |
AHRQ pub - no. 22(23)-EHC037 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Holmer, Haley K. [VerfasserIn] |
|---|
| Links: |
www.ncbi.nlm.nih.gov [teilw. kostenfrei] |
|---|
| Themen: |
Antibody Formation |
|---|
| Anmerkungen: |
Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed March 9, 2023) |
|---|
| Umfang: |
1 online resource (1 PDF file (40 pages)) ; illustrations. |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1869385047 |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 1869385047 | ||
| 003 | DE-627 | ||
| 005 | 20231108071611.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231106s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)1869385047 | ||
| 035 | |a (DE-599)KEP097145815 | ||
| 035 | |a (OCoLC)1408055822 | ||
| 035 | |a (NCBI)9918538123506676 | ||
| 035 | |a (EBP)097145815 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Holmer, Haley K. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antibody response following SARS-CoV-2 infection and implications for immunity |b final update of a rapid, living review |c Haley K. Holmer [and 6 others] |
| 250 | |a Version 3.0. | ||
| 264 | 1 | |a [Rockville, Md.] |b Agency for Healthcare Research and Quality |c July 2022 | |
| 300 | |a 1 online resource (1 PDF file (40 pages)) |b illustrations. | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a Rapid evidence product | |
| 490 | 0 | |a AHRQ pub |v no. 22(23)-EHC037 | |
| 500 | |a Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed March 9, 2023) | ||
| 520 | |a In January 2022, we published an evolving rapid review, meta-analysis, and data visualization that compared the risk of reinfection in adults with prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to the risk of infection in adults without a prior infection. We found that prior infection with the Alpha variant or the wild-type SARS-CoV-2 virus reduced the risk of another infection by 80–97 percent (pooled estimate 87%; 95% confidence interval [CI] 84–90%) compared with uninfected individuals in studies with a median followup of 8 months (range 4 to 13 months). Protection remained above 80 percent for at least 7 months. Our original review, published in March 2021,2 described the antibody response after infection with the SARS-CoV-2 virus, but found little information on the duration of the response beyond 6 months or on antibody formation in asymptomatic patients or in individuals who are immunocompromised. | ||
| 650 | 2 | |a COVID-19 |x immunology | |
| 650 | 2 | |a Antibody Formation |x immunology | |
| 650 | 2 | |a COVID-19 Serological Testing |x methods | |
| 650 | 2 | |a Immunologic Factors |x analysis | |
| 655 | 2 | |a Systematic Review | |
| 710 | 2 | |a United States. |b Agency for Healthcare Research and Quality, |e MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/books/NBK587153/ |m X:NCBI |x Verlag |z teilw. kostenfrei |
| 912 | |a ZDB-193-NCB | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a ISIL_DE-18 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a GBV_ILN_22_i06404 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a ISIL_DE-7 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a ISIL_DE-354 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a ISIL_DE-180 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a ISIL_DE-15 | ||
| 951 | |a BO | ||
| 980 | |2 22 |1 01 |x 0018 |b 4404292554 |h h64 NCBI |y zi06404 |z 08-11-23 | ||
| 980 | |2 40 |1 01 |x 0007 |b 4404291299 |h OLR-NCB-BOOKSHELF |y xsn |z 08-11-23 | ||
| 980 | |2 74 |1 01 |x 0354 |b 4404289960 |c 09 |f E-Bibl |d EM 0000 |e --%%-- |j --%%-- |y ze |z 08-11-23 | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 4402962196 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 06-11-23 | ||
| 980 | |2 2009 |1 01 |x DE-180 |b 440296377X |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 06-11-23 | ||
| 980 | |2 2010 |1 01 |x DE-15 |b 4402963788 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 06-11-23 | ||
| 981 | |2 22 |1 01 |x 0018 |r https://www.ncbi.nlm.nih.gov/books/NBK587153/ | ||
| 981 | |2 40 |1 01 |x 0007 |y Volltext, Open Access |r https://www.ncbi.nlm.nih.gov/books/NBK587153/ | ||
| 981 | |2 74 |1 01 |x 0354 |r https://www.ncbi.nlm.nih.gov/books/NBK587153/ | ||
| 981 | |2 2003 |1 01 |x DE-25 |r https://www.ncbi.nlm.nih.gov/books/NBK587153/ | ||
| 981 | |2 2010 |1 01 |x DE-15 |y Online-Zugriff |r https://www.ncbi.nlm.nih.gov/books/NBK587153/ | ||
| 985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
| 985 | |2 74 |1 01 |x 0354 |a EM 0000 | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 NCBI | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 freie Ressource | ||
| 995 | |2 40 |1 01 |x 0007 |a OLR-NCB-BOOKSHELF | ||